Rates of Visual Field Change in Eyes With Optic Disc Drusen.
Journal
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
ISSN: 1536-5166
Titre abrégé: J Neuroophthalmol
Pays: United States
ID NLM: 9431308
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
pmc-release:
01
09
2024
medline:
22
8
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
Optic disc drusen (ODD) are calcified deposits in the prelaminar portion of the optic nerve head. Although often asymptomatic, these deposits can cause progressive visual field defects and vision loss. The purpose of this study was to evaluate rates of functional loss in eyes with ODD and to investigate risk factors associated with rates of visual field progression. This was a retrospective cohort study including 65 eyes of 43 patients with ODD from the Duke Ophthalmic Registry. All eyes had at least 12 months of follow-up and at least 3 reliable standard automated perimetry (SAP) tests. Linear mixed models were used to estimate rates of SAP mean deviation (MD) loss over time. Univariable and multivariable models were used to assess the effect of clinical variables and intraocular pressure (IOP) on rates of change. Subjects were followed for an average of 7.6 ± 5.3 years. The mean rate of SAP MD change was -0.23 ± 0.26 dB/year, ranging from -1.19 to 0.13 dB/year. Fifty-seven eyes (87.7%) had slow progression (slower than -0.5 dB/year), 6 eyes (9.2%) had moderate progression (between -0.5 dB/year and -1 dB/year), and 2 eyes (3.1%) had fast progression (faster than -1 dB/year). In multivariable models, older age and worse SAP MD at baseline were significantly associated with faster rates of change. Mean IOP was not associated with faster rates of MD change in both univariable and multivariable analyses. Most eyes with ODD had slow rates of visual field loss over time. Age and baseline severity were significantly associated with faster rates of visual field loss.
Sections du résumé
BACKGROUND
Optic disc drusen (ODD) are calcified deposits in the prelaminar portion of the optic nerve head. Although often asymptomatic, these deposits can cause progressive visual field defects and vision loss. The purpose of this study was to evaluate rates of functional loss in eyes with ODD and to investigate risk factors associated with rates of visual field progression.
METHODS
This was a retrospective cohort study including 65 eyes of 43 patients with ODD from the Duke Ophthalmic Registry. All eyes had at least 12 months of follow-up and at least 3 reliable standard automated perimetry (SAP) tests. Linear mixed models were used to estimate rates of SAP mean deviation (MD) loss over time. Univariable and multivariable models were used to assess the effect of clinical variables and intraocular pressure (IOP) on rates of change.
RESULTS
Subjects were followed for an average of 7.6 ± 5.3 years. The mean rate of SAP MD change was -0.23 ± 0.26 dB/year, ranging from -1.19 to 0.13 dB/year. Fifty-seven eyes (87.7%) had slow progression (slower than -0.5 dB/year), 6 eyes (9.2%) had moderate progression (between -0.5 dB/year and -1 dB/year), and 2 eyes (3.1%) had fast progression (faster than -1 dB/year). In multivariable models, older age and worse SAP MD at baseline were significantly associated with faster rates of change. Mean IOP was not associated with faster rates of MD change in both univariable and multivariable analyses.
CONCLUSIONS
Most eyes with ODD had slow rates of visual field loss over time. Age and baseline severity were significantly associated with faster rates of visual field loss.
Identifiants
pubmed: 36728098
doi: 10.1097/WNO.0000000000001801
pii: 00041327-990000000-00280
pmc: PMC10352462
mid: NIHMS1854827
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-358Subventions
Organisme : NEI NIH HHS
ID : R01 EY029885
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY031898
Pays : United States
Informations de copyright
Copyright © 2023 by North American Neuro-Ophthalmology Society.
Déclaration de conflit d'intérêts
T. Estrela, A. A. Jammal, and M. El-Dairi have no conflicts of interest to report. F. A. Medeiros reports the following: Aerie Pharmaceuticals, Allergan, Annexon, Biogen, Carl Zeiss Meditec, Galimedix, Google Inc., Heidelberg Engineering, nGoggle Inc., Novartis, Stealth Biotherapeutics, Reichert, Genentech, Stuart Therapeutics.
Références
Curr Neurol Neurosci Rep. 2008 Sep;8(5):404-8
pubmed: 18713576
J Neuroophthalmol. 2004 Jun;24(2):125-9
pubmed: 15179065
J Glaucoma. 2012 Mar;21(3):147-54
pubmed: 21423039
Acta Ophthalmol (Copenh). 1983 Dec;61(6):1057-66
pubmed: 6659908
Ophthalmic Res. 2019;61(3):153-158
pubmed: 29084401
Eye (Lond). 2018 May;32(5):924-930
pubmed: 29456252
Int J Ophthalmol. 2017 Sep 18;10(9):1430-1435
pubmed: 28944204
Surv Ophthalmol. 2002 Nov-Dec;47(6):515-32
pubmed: 12504737
Graefes Arch Clin Exp Ophthalmol. 2014 Oct;252(10):1653-60
pubmed: 25128962
Acta Ophthalmol. 2014 Jun;92(4):e286-91
pubmed: 24456173
Neuroophthalmology. 2019 Dec 12;44(5):290-293
pubmed: 33012917
J Glaucoma. 2008 Mar;17(2):100-4
pubmed: 18344754
Invest Ophthalmol Vis Sci. 2014 Jun 10;55(7):4135-43
pubmed: 24917147
Ophthalmologe. 2008 Jul;105(7):693-710
pubmed: 18592250
Am J Ophthalmol. 2021 Feb;222:238-247
pubmed: 32450065
Biometrics. 1982 Dec;38(4):963-74
pubmed: 7168798
Ophthalmology. 2022 Feb;129(2):161-170
pubmed: 34474070
Am J Ophthalmol. 2005 Jun;139(6):1062-6
pubmed: 15953437